Niagen Bioscience’s (NAGE) Buy Rating Reiterated at Canaccord Genuity Group

Niagen Bioscience (NASDAQ:NAGE)‘s stock had its “buy” rating reaffirmed by equities researchers at Canaccord Genuity Group in a report released on Tuesday,Benzinga reports. They presently have a $13.00 target price on the stock. Canaccord Genuity Group’s price target would indicate a potential upside of 203.74% from the stock’s previous close.

Several other equities analysts have also recently weighed in on NAGE. Wall Street Zen upgraded Niagen Bioscience from a “hold” rating to a “buy” rating in a report on Saturday. Weiss Ratings reissued a “hold (c)” rating on shares of Niagen Bioscience in a research note on Thursday, January 22nd. Three research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $16.00.

Niagen Bioscience Trading Up 1.9%

NAGE stock opened at $4.28 on Tuesday. Niagen Bioscience has a 1-year low of $4.16 and a 1-year high of $14.69. The firm has a market cap of $342.74 million, a PE ratio of 21.40 and a beta of 2.12. The business’s 50-day moving average price is $5.19 and its two-hundred day moving average price is $6.54.

Institutional Trading of Niagen Bioscience

Hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. acquired a new position in Niagen Bioscience during the third quarter worth $37,522,000. Arrowstreet Capital Limited Partnership acquired a new stake in Niagen Bioscience in the 3rd quarter valued at $13,405,000. UBS Group AG bought a new stake in Niagen Bioscience during the 3rd quarter worth about $11,160,000. Qube Research & Technologies Ltd acquired a new position in shares of Niagen Bioscience during the 3rd quarter worth about $8,175,000. Finally, Millennium Management LLC acquired a new position in shares of Niagen Bioscience during the 3rd quarter worth about $7,224,000. 15.41% of the stock is currently owned by institutional investors and hedge funds.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.